The effects of Teneligliptin on endothelial function in type 2 diabetes mellitus with chronic kidney disease

The effects of Teneligliptin on endothelial function in type 2 diabetes mellitus with chronic kidney disease - Effects of Teneligliptin on endothelial function

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017180

Enrollment

Registered

2015-04-20

Start date

2014-03-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus with chronic kidney disease

Interventions

Type 2 daiabetes mellitus with chronic kidney disease recieving sitagliptin (25-50 mg / day) treatment. Type 2 daiabetes mellitus with chronic kidney disease recieving 20mg teneligliptin treatment sw

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The study subjects were type 2 diabetes mellitus with chronic kidney disease whose hemoglobin A1c (HbA1c) was lower than 10.0% [NGSP] despite treatment with sitagliptin (25-50 mg/day) for at least 4 weeks.All patients had visited the outpatient clinic of Dkkyo Medical University

Exclusion criteria

Exclusion criteria: Exclusion criteria were (1) type 1 diabetes, (2) severe complications of diabetes, (3) severe liver dysfunction (4) severe infections (5) pregnant or nursing women and those who might be pregnant (6) alcoholism, and (7) any patients whom the investigators judged to be inappropriate for this study.

Design outcomes

Primary

Measure	Time frame
The changes in endothelial function and oxidative stress	—

Countries

Japan

Contacts

Public ContactChie Aoki

Dokkyo Medical University Endocrinology and Metabolism

C-aoki@dokkyomed.ac.jp0282-87-2150

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026